Baxter Revenue 2010-2025 | BAX
Baxter annual/quarterly revenue history and growth rate from 2010 to 2025. Revenue can be defined as the amount of money a company receives from its customers in exchange for the sales of goods or services. Revenue is the top line item on an income statement from which all costs and expenses are subtracted to arrive at net income.
- Baxter revenue for the quarter ending March 31, 2025 was $2.625B, a 5.42% increase year-over-year.
- Baxter revenue for the twelve months ending March 31, 2025 was $10.771B, a 15.36% increase year-over-year.
- Baxter annual revenue for 2024 was $10.636B, a 2.66% increase from 2023.
- Baxter annual revenue for 2023 was $10.36B, a 3.01% increase from 2022.
- Baxter annual revenue for 2022 was $10.057B, a 17.2% decline from 2021.
| Baxter Annual Revenue (Millions of US $) |
|
|---|---|
| 2024 | $10,636 |
| 2023 | $10,360 |
| 2022 | $10,057 |
| 2021 | $12,146 |
| 2020 | $11,673 |
| 2019 | $11,362 |
| 2018 | $11,099 |
| 2017 | $10,584 |
| 2016 | $10,163 |
| 2015 | $9,968 |
| 2014 | $10,719 |
| 2013 | $9,413 |
| 2012 | $13,936 |
| 2011 | $13,893 |
| 2010 | $12,843 |
| 2009 | $12,562 |
| Baxter Quarterly Revenue (Millions of US $) |
|
|---|---|
| 2025-03-31 | $2,625 |
| 2024-12-31 | $1,635 |
| 2024-09-30 | $2,699 |
| 2024-06-30 | $3,812 |
| 2024-03-31 | $2,490 |
| 2023-12-31 | $541 |
| 2023-09-30 | $2,599 |
| 2023-06-30 | $3,707 |
| 2023-03-31 | $3,513 |
| 2022-12-31 | $-853 |
| 2022-09-30 | $3,609 |
| 2022-06-30 | $3,594 |
| 2022-03-31 | $3,707 |
| 2021-12-31 | $2,876 |
| 2021-09-30 | $3,226 |
| 2021-06-30 | $3,098 |
| 2021-03-31 | $2,946 |
| 2020-12-31 | $3,181 |
| 2020-09-30 | $2,972 |
| 2020-06-30 | $2,718 |
| 2020-03-31 | $2,802 |
| 2019-12-31 | $3,039 |
| 2019-09-30 | $2,851 |
| 2019-06-30 | $2,834 |
| 2019-03-31 | $2,638 |
| 2018-12-31 | $2,819 |
| 2018-09-30 | $2,761 |
| 2018-06-30 | $2,842 |
| 2018-03-31 | $2,677 |
| 2017-12-31 | $2,797 |
| 2017-09-30 | $2,707 |
| 2017-06-30 | $2,605 |
| 2017-03-31 | $2,475 |
| 2016-12-31 | $2,645 |
| 2016-09-30 | $2,558 |
| 2016-06-30 | $2,585 |
| 2016-03-31 | $2,375 |
| 2015-12-31 | $2,603 |
| 2015-09-30 | $2,487 |
| 2015-06-30 | $2,475 |
| 2015-03-31 | $2,403 |
| 2014-12-31 | $2,789 |
| 2014-09-30 | $2,709 |
| 2014-06-30 | $4,154 |
| 2014-03-31 | $3,848 |
| 2013-12-31 | $4,322 |
| 2013-09-30 | $3,710 |
| 2013-06-30 | $3,669 |
| 2013-03-31 | $3,448 |
| 2012-12-31 | $3,499 |
| 2012-09-30 | $3,477 |
| 2012-06-30 | $3,572 |
| 2012-03-31 | $3,388 |
| 2011-12-31 | $3,594 |
| 2011-09-30 | $3,479 |
| 2011-06-30 | $3,536 |
| 2011-03-31 | $3,284 |
| 2010-12-31 | $3,498 |
| 2010-09-30 | $3,224 |
| 2010-06-30 | $3,194 |
| 2010-03-31 | $2,927 |
| 2009-12-31 | $3,470 |
| 2009-09-30 | $3,145 |
| 2009-06-30 | $3,123 |
| 2009-03-31 | $2,824 |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Medical Products Manufacturing | $15.529B | $10.636B |
| Baxter International Inc. is a global medical technology company. The company consists of renal and hospital products, providing items such as kidney-dialysis equipment, infusion pumps, and intravenous (IV) solutions. Baxter has been reporting through six revenue segments. Renal Care, Medication Delivery, Pharmaceuticals, Clinical Nutrition, Advanced Surgery, Acute Therapies and Other. Baxter's Renal segment primarily consists of Peritoneal Dialysis (PD) and Hemodialysis (HD) therapies. The portfolio addresses the needs of patients with kidney failure or kidney disease, and their healthcare providers, with a comprehensive range of therapeutic options across home, in-center, and hospital settings for better individualized care. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Abbott Laboratories (ABT) | United States | $232.407B | 27.95 |
| Boston Scientific (BSX) | United States | $151.037B | 37.81 |
| Stryker (SYK) | United States | $146.527B | 30.64 |
| EssilorLuxottica (ESLOY) | France | $129.703B | 0.00 |
| Medtronic (MDT) | Ireland | $112.146B | 15.90 |
| Lonza Group Ag (LZAGY) | Switzerland | $50.313B | 0.00 |
| Haleon (HLN) | United Kingdom | $49.844B | 28.38 |
| ResMed (RMD) | United States | $36.979B | 27.78 |
| Agilent Technologies (A) | United States | $32.895B | 21.44 |
| GE HealthCare Technologies (GEHC) | United States | $32.794B | 15.57 |
| Terumo (TRUMY) | Japan | $26.561B | 34.50 |
| Koninklijke Philips (PHG) | Netherlands | $22.051B | 15.85 |
| Insulet (PODD) | United States | $21.941B | 86.12 |
| Zimmer Biomet Holdings (ZBH) | United States | $18.277B | 11.74 |
| Smith & Nephew SNATS (SNN) | United Kingdom | $13.253B | 0.00 |
| Demant (WILYY) | Denmark | $8.854B | 0.00 |
| Sunny Optical Technology (SNPTF) | China | $8.430B | 0.00 |
| Bio-Rad Laboratories (BIO) | United States | $5.971B | 20.78 |
| Lantheus Holdings (LNTH) | United States | $5.642B | 14.23 |
| Prestige Consumer Healthcare (PBH) | United States | $4.203B | 18.78 |
| Perrigo (PRGO) | Ireland | $3.596B | 9.11 |
| Shandong Weigao Medical Polymer (SHWGF) | China | $3.459B | 0.00 |
| Haemonetics (HAE) | United States | $3.385B | 15.42 |
| ICU Medical (ICUI) | United States | $3.275B | 24.15 |
| Envista Holdings (NVST) | United States | $3.174B | 26.38 |
| GN Store Nord (GNNDY) | Denmark | $2.180B | 18.06 |
| QuidelOrtho (QDEL) | United States | $1.997B | 13.73 |
| LeMaitre Vascular (LMAT) | United States | $1.901B | 42.49 |
| AtriCure (ATRC) | United States | $1.730B | 0.00 |
| Acuren (TIC) | United States | $1.271B | 0.00 |
| AdaptHealth (AHCO) | United States | $1.201B | 12.19 |
| Neogen (NEOG) | United States | $1.131B | 14.47 |
| BioLife Solutions (BLFS) | United States | $1.126B | 0.00 |
| Green Thumb Industries (GTBIF) | United States | $1.100B | 24.74 |
| Kestra Medical Technologies (KMTS) | United States | $1.063B | 0.00 |
| Phibro Animal Health (PAHC) | United States | $0.976B | 12.48 |
| InMode (INMD) | Israel | $0.895B | 9.02 |
| Capricor Therapeutics (CAPR) | United States | $0.650B | 0.00 |
| Evolus (EOLS) | United States | $0.647B | 0.00 |
| CeriBell (CBLL) | United States | $0.647B | 0.00 |
| Owens & Minor (OMI) | United States | $0.619B | 5.13 |
| Maravai LifeSciences Holdings (MRVI) | United States | $0.609B | 0.00 |
| Curaleaf Holdings (CURLF) | Canada | $0.584B | 0.00 |
| Valneva SE (VALN) | France | $0.515B | 0.00 |
| Surmodics (SRDX) | United States | $0.420B | 0.00 |
| Tilray Brands (TLRY) | Canada | $0.408B | 0.00 |
| VAREX IMAGING (VREX) | United States | $0.347B | 12.76 |
| SNDL (SNDL) | Canada | $0.347B | 0.00 |
| Aurora Cannabis (ACB) | Canada | $0.322B | 57.20 |
| Canopy Growth (CGC) | Canada | $0.313B | 0.00 |
| SEMPERIT AG HLD (SEIGY) | Austria | $0.291B | 0.00 |
| Cerus (CERS) | United States | $0.289B | 0.00 |
| Viemed Healthcare (VMD) | United States | $0.266B | 22.40 |
| Cresco Labs (CRLBF) | United States | $0.265B | 0.00 |
| Sanara MedTech (SMTI) | United States | $0.262B | 0.00 |
| ZimVie (ZIMV) | United States | $0.261B | 11.87 |
| Sanuwave Health (SNWV) | United States | $0.239B | 0.00 |
| Omeros (OMER) | United States | $0.221B | 0.00 |
| OraSure Technologies (OSUR) | United States | $0.216B | 0.00 |
| Biote (BTMD) | United States | $0.210B | 5.89 |
| Quanterix (QTRX) | United States | $0.209B | 0.00 |
| TriSalus Life Sciences (TLSI) | United States | $0.204B | 0.00 |
| Brainsway (BWAY) | Israel | $0.197B | 52.25 |
| High Tide (HITI) | Canada | $0.193B | 0.00 |
| Verano Holdings (VRNOF) | United States | $0.192B | 0.00 |
| Utah Medical Products (UTMD) | United States | $0.182B | 14.86 |
| Organigram Global (OGI) | Canada | $0.181B | 0.00 |
| Exagen (XGN) | United States | $0.154B | 0.00 |
| Vireo Growth (VREOF) | United States | $0.139B | 0.00 |
| FitLife Brands (FTLF) | United States | $0.134B | 16.54 |
| Jin Medical (ZJYL) | China | $0.120B | 0.00 |
| MacroGenics (MGNX) | United States | $0.112B | 0.00 |
| Oramed Pharmaceuticals (ORMP) | United States | $0.091B | 0.00 |
| Veru (VERU) | United States | $0.091B | 0.00 |
| Fonar (FONR) | United States | $0.090B | 11.59 |
| Quipt Home Medical (QIPT) | United States | $0.087B | 0.00 |
| TerrAscend (TSNDF) | Canada | $0.082B | 0.00 |
| Agape ATP (ATPC) | $0.077B | 0.00 | |
| InterCure (INCR) | Israel | $0.068B | 0.00 |
| Cytosorbents (CTSO) | United States | $0.066B | 0.00 |
| Zynex (ZYXI) | United States | $0.066B | 0.00 |
| Apyx Medical (APYX) | United States | $0.063B | 0.00 |
| ImmuCell (ICCC) | United States | $0.059B | 0.00 |
| Jushi Holdings (JUSHF) | United States | $0.058B | 0.00 |
| Modular Medical (MODD) | United States | $0.046B | 0.00 |
| United-Guardian (UG) | United States | $0.038B | 13.14 |
| Nephros (NEPH) | United States | $0.036B | 48.00 |
| Rockwell Medical (RMTI) | United States | $0.035B | 0.00 |
| Safety Shot (SHOT) | United States | $0.020B | 0.00 |
| Allurion Technologies (ALUR) | United States | $0.020B | 0.00 |
| Cellectar Biosciences (CLRB) | United States | $0.017B | 0.00 |
| INLIF (INLF) | $0.016B | 0.00 | |
| Meihua Medical Technologies (MHUA) | China | $0.015B | 0.00 |
| Flora Growth (FLGC) | United States | $0.014B | 0.00 |
| Trinity Biotech (TRIB) | Ireland | $0.012B | 0.00 |
| Innovative Eyewear (LUCY) | United States | $0.009B | 0.00 |
| IM Cannabis (IMCC) | Canada | $0.006B | 0.00 |
| Senestech (SNES) | United States | $0.005B | 0.00 |
| GlucoTrack (GCTK) | United States | $0.004B | 0.00 |
| Akanda (AKAN) | Canada | $0.002B | 0.00 |
| Sharps Technology (STSS) | United States | $0.000B | 0.00 |
| InVivo Therapeutics Holdings (NVIVQ) | United States | $0.000B | 0.00 |